TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
TG Therapeutics presented first-in-human-class Phase 1 data for azer-cel, an off-the-shelf allogeneic CD19 CAR-T, in progressive multiple sclerosis at the ACTRIMS-ECTRIMS meeting in Toronto. Across 26 heavily pre-treated participants, no Grade 3+ cytokine release syndrome, ICANS, or graft-versus-host disease was observed, and 89% of evaluable patients had stable or improved EDSS disability scores at Day 90, with three achieving at least 2.0-point improvements. B-cell depletion in blood and CSF confirmed biological activity, and dose escalation with longer follow-up is ongoing.
Key figures
- Drug Name
- azercabtagene zapreleucel (azer-cel)
- Phase Of Trial
- Phase 1
- Dose levels
- 30 million to 500 million CAR T-cells
- Participants
- 26
- Grade3plus crs
- 0
- Median baseline edss
- 6
- Median followup months
- 4.9
- Stable or improved edss day90
- 89% (16/18)
- Stable or improved edss day180
- 88% (7/8)
- B cell depletion below 10 cells ul
- 96% (25/26)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.